...
首页> 外文期刊>Clinical Interventions in Aging >Comparative clinicopathological and outcome analysis of differentiated thyroid cancer in Saudi patients aged below 60 years and above 60 years
【24h】

Comparative clinicopathological and outcome analysis of differentiated thyroid cancer in Saudi patients aged below 60 years and above 60 years

机译:沙特患者低于60岁及60岁以下的沙特患者分化甲状腺癌的比较临床病理学和结果分析

获取原文

摘要

Introduction: The aim of this study was to evaluate the treatment outcomes of differentiated thyroid cancer in Saudi patients aged above 60 years. Materials and methods: Comparative analysis was performed in 252 patients aged 46–60 years (Group A) and 118 patients aged above 60 years (Group B), who had thyroidectomy, radioactive iodine-131, and thyroid-stimulating hormone suppression therapy between July 2000 and December 2012. Different clinicopathological features, treatment, complications, disease-free survival, and overall survival rates were compared. Results: Mean age of patients in Group A was 51.9 years (range: 46–60), and mean age of those in Group B was 68.6 years (range: 62–97). Group B patients had higher positive lymph nodes (43.2%), P =0.011. The frequency of extrathyroidal extension, multifocality, and lymphovascular space invasion was seen more in Group B than in Group A. Postsurgical complications (permanent hypoparathyroidism, bleeding, and wound infections) were also seen more in Group B ( P =0.043, P =0.011, and P =0.021, respectively). Group B patients experienced more locoregional recurrences (11.0%, P =0.025); similarly, more distant metastases were observed in Group B (15.3%, P =0.003). The 10-year disease-free survival rates were 87.6% in Group A and 70.8% in Group B ( P <0.0001). Conclusion: Differentiated thyroid cancer in patients aged above 60 years are more aggressive biologically and associated with a worse prognosis, and the morbidity is significantly high as compared to patients aged below 60 years.
机译:介绍:本研究的目的是评估在60岁以上的沙特患者中分化的甲状腺癌的治疗结果。材料和方法:对比较分析在46-60岁(A组)和68岁以上患者(B组)的118名患者中进行了比较分析,患有甲状腺切除术,放射性碘-131和甲状腺刺激激素抑制疗法2000年和2012年12月。比较了不同的临床病理特征,治疗,并发症,无病生存和总存活率。结果:A组患者的平均年龄为51.9岁(范围:46-60),B组的平均年龄为68.6岁(范围:62-97)。 B组患者具有更高的阳性淋巴结(43.2%),P = 0.011。在B组中,B组脱离rootival延伸,多焦度和淋巴血管空间侵袭的频率也更多地观察到B组中的后期并发症(永久性低丙酮毒性,出血和伤口感染)(P = 0.043,P = 0.011和p = 0.021分别)。 B组患者经历了更多的招生复发(11.0%,P = 0.025);类似地,在B组(15.3%,P = 0.003)中观察到更多远离转移。 10年的易病存活率为A组和B组的87.6%,B组(P <0.0001)。结论:60岁以上患者的分化甲状腺癌在生物学上更具侵略性,与较差的预后相关,与60岁以下的患者相比,发病率明显高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号